The Effect on Total Mortality of Adding Inhaled Corticosteroids to Long-Acting Bronchodilators for COPD: A Real Practice Analysis in Italy

References

• Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management, and Prevention of COPD, 2014 update. Available from: http://www.goldcopd.org/.
   Google Scholar
• Hanania NA. The impact of inhaled corticosteroid and long-acting beta-agonist combination therapy on outcomes in COPD. Pulm Pharmacol Ther 2008; 21:540–550.
   PubMed Web of Science ®Google Scholar
• O'Donnell DE, Aaron S, Bourbeau J, et al. Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease—2007 update. Can Respir J 2007; 14(Suppl B): 5B–32B.
   PubMed Web of Science ®Google Scholar
• Chong J, Karner C, Poole P. Tiotropium versus long-acting beta-agonists for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2012; 9: CD009157.
   PubMed Web of Science ®Google Scholar
• Pauwels RA, Lofdahl CG, Laitinen LA, et al. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society study on chronic obstructive pulmonary disease. N Engl J Med 1999; 340:1948–1953.
   PubMed Web of Science ®Google Scholar
• Vestbo J, Sorensen T, Lange P, et al. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 1999; 353:1819–1823.
   PubMed Web of Science ®Google Scholar
• Burge PS, Calverley PM, Jones PW, et al. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. Br Med J 2000; 320:1297–1303.
   PubMed Web of Science ®Google Scholar
• Yang IA, Clarke MS, Sim EH, et al. Inhaled corticosteroids for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2012; 7:CD002991.
   PubMed Web of Science ®Google Scholar
• Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, Yates JC, Vestbo J; TORCH investigators. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007; 356(8):775–789.
   PubMed Web of Science ®Google Scholar
• Nannini L, Cates CJ, Lasserson TJ, Poole P. Combined corticosteroid and long-acting beta-agonist in one inhaler versus placebo for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2007; 4:CD003794.
   Google Scholar
• Nannini L, Cates CJ, Lasserson TJ, Poole P. Combined corticosteroid and long-acting beta-agonist in one inhaler versus inhaled steroids for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2007; 4:CD006826.
   PubMed Web of Science ®Google Scholar
• Nannini L, Lasserson TJ, Poole P. Combined corticosteroid and long-acting beta(2)-agonist in one inhaler versus long-acting beta(2)-agonists for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2012; 9:CD006829.
   PubMed Web of Science ®Google Scholar
• Kirchmayer U, Agabiti N, Belleudi V, et al. Socio-demographic differences in adherence to evidence-based drug therapy after hospital discharge from acute myocardial infarction: a population-based cohort study in Rome, Italy. J Clin Pharm Ther 2012; 37(1):37–44.
   PubMed Web of Science ®Google Scholar
• Fano V, D'Ovidio M, Del Zio K, et al. The role of the quality of Hospital Discharge Records on the comparative evaluation of outcomes: the example of Chronic Obstructive Pulmonary Disease. Epidemiol Prev 2012; 36(3–4):172–179.
   PubMed Web of Science ®Google Scholar
• Catalan VS, LeLorier J. Predictors of long-term persistence on statins in a subsidized clinical population. Value Health 2000; 3(6): 417–426.
   PubMedGoogle Scholar
• Schneeweiss S, Seeger JD, Maclure M, et al. Performance of comorbidity scores to control for confounding in epidemiologic studies using claims data. Am J Epidemiol 2001; 154(9):854–864.
   PubMed Web of Science ®Google Scholar
• Huybrechts KF, Schneeweiss S, Gerhard T, Olfson M, Avorn J, Levin R, Lucas JA, Crystal S. Comparative safety of antipsychotic medications in nursing home residents. J Am Geriatr Soc. 2012; 60(3):420–429.
   PubMed Web of Science ®Google Scholar
• Braitman LE, Rosenbaum PR. Rare outcomes, common treatments: Analytic strategies using propensity scores. Ann Intern Med 2002; 137:693–695.
   PubMed Web of Science ®Google Scholar
• Caliendo M. Microeconometric Evaluation of Labour Market Policies. Lecture Notes in Economics and Mathematical Systems. Springer-Verlag, Berlin, Germany; 2006.
   Google Scholar
• Patorno E, Grotta A, Bellocco R, Schneeweiss S. Propensity score methodology for confounding control in health care utilization databases. Epidemiology Biostatistics and Public Health 2013; 10(3):6.
   Google Scholar
• Rothman KJ, Greenland S, Lash TL: Modern Epidemiology. Third edition, Lippincott Williams and Wilkins, Philadelphia, PA; 2008.
   Google Scholar
• Glynn RJ, Schneeweiss S, Stürmer T. Indications for Propensity Scores and Review of Their Use in Pharmacoepidemiology. Basic Clin Pharmacol Toxicol 2006; 98(3):253–259.
   PubMed Web of Science ®Google Scholar
• Rosenbaum PR, Rubin DB. Reducing bias in observational studies using subclassification on the propensity score. J Amer Statistical Association 1984; 79:516–524.
   Web of Science ®Google Scholar
• Lou P, Chen P, Zhang P, Yu J, Wang Y, Chen N, Zhang L, Wu H, Zhao J. Effects of smoking, depression, and anxiety on mortality in COPD patients: a prospective study. Respir Care 2014; 59(1):54–61.
   PubMed Web of Science ®Google Scholar
• Schneeweiss S. Sensitivity analysis and external adjustment for unmeasured confounders in epidemiologic database studies of therapeutics. Pharmacoepidemiol Drug Saf 2006; 15(5):291–303.
   PubMed Web of Science ®Google Scholar
• Tønnesen P. Smoking cessation and COPD. Eur Respir Rev 2013; 22(127):37–43.
   PubMedGoogle Scholar
• O’Donnell DE, Hernandez P, Kaplan A, Aaron S, Bourbeau J, Marciniuk D, Balter M, Ford G, Gervais A, Lacasse Y, Maltais F, Road J, Rocker G, Sin D, Sinuff T, Voduc N. Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease - 2008 update - highlights for primary care. Can Respir J 2008; 15 Suppl A:1A-8A.
   Google Scholar
• National Institute of Clinical Excellence (NICE). Chronic obstructive pulmonary disease: Management of chronic obstructive pulmonary disease in adults in primary and secondary care. Update NICE Clinical Guideline 2010. National Clinical Guideline Centre, Royal College of Physicians 2010; London (UK).
   Google Scholar
• Wedzicha JA, Calverley PM, Seemungal TA, Hagan G, Ansari Z, Stockley RA; INSPIRE Investigators. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med 2008; 177(1):19–26.
   PubMed Web of Science ®Google Scholar
• Celli B, Decramer M, Kesten S, Liu D, Mehra S, Tashkin DP; UPLIFT Study Investigators. Mortality in the 4-year trial of tiotropium (UPLIFT) in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009; 180(10):948–955.
   PubMed Web of Science ®Google Scholar
• Barnes PJ. Cellular and molecular mechanisms of chronic obstructive pulmonary disease. Clin Chest Med 2014; 35:71–86. Review.
   PubMed Web of Science ®Google Scholar
• Gan WQ, Man SF, Senthilselvan A, Sin DD. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax 2004; 59:574–580.
   PubMed Web of Science ®Google Scholar
• Dahl M, Vestbo J, Lange P, Bojesen SE, Tybjaerg-Hansen A, Nordestgaard BG. C-reactive protein as a predictor of prognosis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2007; 175:250–255.
   PubMed Web of Science ®Google Scholar
• Agustí A, Edwards LD, Rennard SI, MacNee W, Tal-Singer R, Miller BE, Vestbo J, Lomas DA, Calverley PM, Wouters E, Crim C, Yates JC, Silverman EK, Coxson HO, Bakke P, Mayer RJ, Celli B; evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators. Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype. PLoS One 2012; 7(5):e37483.
   PubMed Web of Science ®Google Scholar
• Soler-Cataluña JJ, Martínez-García MA, Román Sánchez P, Salcedo E, Navarro M, Ochando R. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax 2005; 60:925–931.
   PubMed Web of Science ®Google Scholar
• Qaseem A, Wilt TJ, Weinberger SE, Hanania NA, Criner G, van der Molen T, Marciniuk DD, Denberg T, Schünemann H, Wedzicha W, MacDonald R, Shekelle P; American College of Physicians; American College of Chest Physicians; American Thoracic Society; European Respiratory Society. Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society. Ann Intern Med 2011; 155(3):179–191.
   PubMed Web of Science ®Google Scholar
• Hurst JR, Vestbo J, Anzueto A, Locantore N, Müllerova H, Tal-Singer R, Miller B, Lomas DA, Agusti A, Macnee W, Calverley P, Rennard S, Wouters EF, Wedzicha JA; Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 2010; 363(12):1128–1138.
   PubMed Web of Science ®Google Scholar
• Wedzicha JA, Brill SE, Allinson JP, Donaldson GC. Mechanisms and impact of the frequent exacerbator phenotype in chronic obstructive pulmonary disease. BMC Med 2013; 11:181. Review.
   PubMed Web of Science ®Google Scholar
• Wedzicha JA, Rabe KF, Martinez FJ, Bredenbröker D, Brose M, Goehring UM, Calverley PM. Efficacy of roflumilast in the COPD frequent exacerbator phenotype. Chest 2013; 143(5):1302–1311.
   PubMed Web of Science ®Google Scholar
• Sin DD, Tu JV. Inhaled corticosteroids and the risk of mortality and readmission in elderly patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 164:580–584.
   PubMed Web of Science ®Google Scholar
• Soriano JB, Vestbo J, Pride NB, Kiri V, Maden C, Maier WC. Survival in COPD patients after regular use of fluticasone propionate and salmeterol in general practice. Eur Respir J 2002; 20:819–825.
   PubMed Web of Science ®Google Scholar
• Kiri VA, Pride NB, Soriano JB, Vestbo J. Inhaled corticosteroids in chronic obstructive pulmonary disease: results from two observational designs free of immortal time bias. Am J Respir Crit Care Med 2005; 172:460–464.
   PubMed Web of Science ®Google Scholar
• Tkacova R, Toth S, Sin DD. Inhaled corticosteroids and survival in COPD patients receiving long-term home oxygen therapy. Respir Med 2006; 100:385–392.
   PubMed Web of Science ®Google Scholar
• Suissa S. Effectiveness of inhaled corticosteroids in chronic obstructive pulmonary disease: immortal time bias in observational studies. Am J Respir Crit Care Med 2003; 168:49–53.
   PubMed Web of Science ®Google Scholar
• Suissa S. Inhaled steroids and mortality in COPD: bias from unaccounted immortal time. Eur Respir J 2004; 23:391–395.
   PubMed Web of Science ®Google Scholar
• Suissa S. Observational studies of inhaled cortico-steroids in chronic obstructive pulmonary disease: misconstrued immortal time bias. Am J Respir Crit Care Med 2006; 173:464–465.
   PubMed Web of Science ®Google Scholar
• Suissa S. Immortal time bias in observational studies of drug effects. Pharmacoepidemiol Drug Saf 2007; 16:241–249.
   PubMed Web of Science ®Google Scholar
• Suissa S. Immortal time bias in pharmacoepidemiology. Am J Epidemiol 2008; 167:492–499.
   PubMed Web of Science ®Google Scholar
• Suissa S. Randomized trials built on sand: Examples from COPD, hormone therapy, and cancer. Rambam Maimonides Med J 2012; 3(3):e0014.
   PubMedGoogle Scholar
• World Health Organization Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC Classification and DDD Assignment 2013 (16th edition). Oslo, Norway, 2012.
   Google Scholar
• Di Martino M, Agabiti N, Bauleo L, Kirchmayer U, Cascini S, Pistelli R, Colamesta V, Patorno E, Pinnarelli L, Fusco D, Perucci CA, Davoli M. Use patterns of long-acting bronchodilators in routine COPD care: the OUTPUL study. COPD 2014; 11(4):414–423.
   PubMedGoogle Scholar
• van Staa TP, Abenhaim L, Leufkens H. A study of the effects of exposure misclassification due to the time-window design in pharmacoepidemiologic studies. J Clin Epidemiol 1994; 47(2):183–189.
   PubMed Web of Science ®Google Scholar